Facts You Need to Understand Madrigal Pharmaceuticals (MDGL) Stock

Small-cap Healthcare company Madrigal Pharmaceuticals has moved 5.8% so far today on a volume of 1,890,576, compared to its average of 450,628. In contrast, the S&P 500 index moved 0.1%.

Madrigal Pharmaceuticals trades 63.04% away from its average analyst target price of $152.42 per share. The 12 analysts following the stock have set target prices ranging from $75 to $203, and on average have given Madrigal Pharmaceuticals a rating of buy.

Anyone interested in buying MDGL should be aware of the facts below:

  • Based on its trailing earning per share of -13.09, Madrigal Pharmaceuticals has a trailing 12 month Price to Earnings (P/E) ratio of -19.0 while the S&P 500 average is 15.97

  • MDGL has a forward P/E ratio of -16.8 based on its forward 12 month price to earnings (Eps) of $-14.83 per share

  • Its Price to Book (P/B) ratio is 16.1 compared to its sector average of 4.07

  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

  • Based in West Conshohocken, the company has 71 full time employees and a market cap of $4,248,629,248.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.